Guidance

MenACWY vaccine: patient group direction (PGD) template

PGD template to support the national Meningococcal group A,C,W and Y (Menveo®, Nimenrix® or MenQuadfi®) vaccination programme.

Applies to England

Documents

Meningococcal group A,C,W and Y vaccine (Menveo®, Nimenrix® or MenQuadfi®) PGD template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of meningococcal group A, C, W and Y conjugate vaccine (MenACWY) to individuals eligible for national routine MenACWY vaccination programme and university freshers (catch-up) programme. It also covers administration of MenACWY vaccine for outbreak control and contacts of confirmed cases, in accordance with the guidance for the public health management of meningococcal disease in the UK.

The MenACWY PGD version 05.00 is valid from 31 July 2023 to 31 July 2025.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics.

Updates to this page

Published 14 July 2015
Last updated 23 June 2023 + show all updates
  1. Added version version 05.00 – see page 2 for change history.

  2. Added version V03.00 – see page 2 for change history.

  3. Added version V03.00 following routine review of PGD prior to expiry.

  4. Added revised PGD v02.00 to replace expiring v01.00 from 1 July 2017

  5. First published.

Sign up for emails or print this page